Business Context and Reporting Period
Company: Amphastar Pharmaceuticals, Inc. (AMPH)
Filing Type: Form 8-K (Current Report)
Date of Report: July 2, 2026
Event: Receipt of an FDA Warning Letter by subsidiary International Medication Systems, Limited ("IMS") regarding its South El Monte, California manufacturing facility.
Key Financial Metrics
This filing is a current report regarding a regulatory event and does not contain financial statements. The text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Regulatory Event
- Event: On July 2, 2026, IMS received an FDA Warning Letter following an inspection conducted in December 2025.
- Cited Violations: The letter cites violations of current Good Manufacturing Practice (CGMP) regulations concerning investigation procedures, environmental monitoring, handling procedures, and manufacturing equipment.
- Operational Status: The Warning Letter does not direct IMS to cease or restrict products, nor does it require a recall. IMS continues to manufacture and supply products from the facility.
- Required Actions: IMS must submit an initial response within 15 working days, conduct a risk assessment, and submit a remediation plan.
Outlook, Risks, and Management Commentary
- Management Response: The Company states it takes the matters seriously and is implementing corrective actions. It is currently evaluating the impact on business operations.
- Uncertainty: The Company provides no assurance that the FDA will be satisfied with the response or regarding the timing of resolution.
- Risks: Until deficiencies are resolved to the FDA's satisfaction, additional regulatory or legal action may be taken without further notice.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from expectations due to regulatory changes and supply chain disruptions.
Investor Verification Checklist
- Verify the specific details of the remediation plan IMS submits to the FDA within the 15-day window.
- Monitor for any subsequent FDA actions, such as product recalls or facility shutdowns, which are not currently mandated but remain a risk.
- Review the Company's next quarterly or annual report for quantified financial impacts related to the remediation costs or operational disruptions.
- Confirm whether the "third party verification" mentioned regarding potential recalls is completed and what its findings are.